FDA rejects Osteal combo therapy to treat joint-implant infections
The FDA late last month rejected Osteal Therapeutics' lead combo therapy that sought to more quickly fight the bacteria or other microorganisms that infect the area around a joint implant. The company has yet to ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.